An observational study in Myocardial Bridging, Obstructive Hypertrophic Cardiomyopathy and Atrial Fibrillation (AF), sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 71 studies in Cardiomyopathy, Hypertrophic with a site in China — 30 open to participants now, 43 under way, 2 of them phase 3. Cardiomyopathy, Hypertrophic · China.
Among the 71 studies in Cardiomyopathy, Hypertrophic with a site in China, this one is the 12th largest by enrollment of the 32 observational ones that give a count, is one of 9 that started in 2022, is one of 32 observational ones, and was the 47th registered.
364 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 117 are open to participants now.
Browse Cardiomyopathy, Hypertrophic studies →30 of the 71 studies in Cardiomyopathy, Hypertrophic with a site in China are open now. Recruiting first, the newest first:
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 18+
Bristol-Myers Squibb · Sites in China
Ages 18+
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
Peking Union Medical College Hospital · Sites in China
Ages 18–85 · Healthy volunteers
SuZhou Sinus Medical Technologies Co.,Ltd · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 5 · Phase 3 7 · Phase 4 3
First in 2011; this study’s year is marked. 9 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 968 is above the median of 259 across 174 observational studies indexed under Cardiomyopathy, Hypertrophic.
Median enrollment 84 across the 39 interventional studies, 608 across the 32 observational. Of the 21 that completed or were terminated, 5 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 71 have an industry lead sponsor. The 10 most frequent:
Chinese Academy of Medical Sciences, Fuwai Hospital is the lead sponsor of 147 studies on the registry; 51 are open to participants now.
Chinese Academy of Medical Sciences, Fuwai Hospital has 6 studies filed under Cardiomyopathy, Hypertrophic — fewer than ten, so there is no comparison to draw.
8 of the studies in Cardiomyopathy, Hypertrophic with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07354646Chinese Academy of Medical Sciences, Fuwai HospitalThe Application of T1 Mapping in Real-World | 2026-12-01 |
| NCT07006493SuZhou Sinus Medical Technologies Co.,LtdREFINE-HCM: Intramyocardial Septal Radiofrequency Ablation for Obstructive Hypertrophic Cardiomyopathy | 2026-12-30 |
| NCT07464132Peking Union Medical College HospitalApplication of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases | 2027-02-17 |
| NCT07846059Bristol-Myers SquibbEvaluation of Mavacamten-Based Practice in Chinese Adults With Obstructive Hypertrophic Cardiomyopathy | 2027-03-31 |
| NCT06794710RenJi HospitalEarly Identification and Treatment of Rare Cardiomyopathy Cohorts | 2027-05-30 |
Add all 8 to your calendar (.ics) → With an account.
Among the 71 studies in Cardiomyopathy, Hypertrophic with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study investigated the impact of myocardial bridging (MB) and its characteristics on preoperative atrial fibrillation and survival in patients with obstructive hypertrophic cardiomyopathy (oHCM). We recruited 968 consecutive patients with oHCM who underwent myectomy at our institution between January 2015 and December 2019, including 144 patients with MB and 824 patients without MB. All patients received angiography before surgery. The diagnosis of preoperative atrial fibrillation was based on 12-lead electrocardiography, 24-hour Holter electrocardiography, or in-hospital electrocardiogram monitoring, which was extracted from patients' medical records. Surgical details and follow-up data were also collected.
Patients diagnosed with obstructive hypertrophic cardiomyopathy who underwent septal myectomy.
Inclusion Criteria:I(i) age ≥ 18 years and (ii) diagnosis of oHCM based on clinical and echocardiographic evaluation.
-
Exclusion Criteria: (i) a history of heart surgery (ii) Patients who had coronary atherosclerosis or myocardial infraction; (iii) Patients who had no angiography records.
-
All patients underwent angiography and without other coronary artery disease.
Procedure: Coronary artery bypass grafting or unroofing
Patients had an MB with \>75% compression degree would receive coronary artery bypass grafting, and those who underwent unroofing may had a depth of MB \< 5mm (whether deal with these MB with a depth \<5mm depends on the surgeon and the period time of patients received a surgery).
All-cause death
Any death occurred one month after discharge
Time frame: One month after discharge
New-onset AF
Patients did not have AF before surgery, and AF occurred one month after discharge.
Time frame: One month after discharge.
Composite endpoints
Composite endpoints including all-cause death, new-onset AF, and readmission due to heart failure, stroke, and other cardiovascular events (such as myocardial infarction, arrhythmia).
Time frame: One month after discharge
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2022 to primary completion in Dec 2022, 11 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cardiomyopathy, Hypertrophic →
Chinese Academy of Medical Sciences, Fuwai Hospital →